No public evidence reviewed for this article establishes one platform as every clinician's first stop. OpenEvidence, Heidi Evidence and Tandem CDS are competing across two different questions: where a clinician can ask with least effort, and which answer is useful enough to trust after checking. Integration can help with the first without settling the second.
Strategic analysis, 14 September 2026. Product descriptions are dated to this review. The proposed comparisons below have not been run and contain no invented product outputs or performance scores.
A destination and a convenient doorway are different advantages
A dedicated reference product succeeds when clinicians deliberately open it because they expect a useful answer. A workflow-integrated product may be considered first because the clinician is already using the surrounding application. Neither advantage is trivial, and neither is sufficient on its own.
The distinction is becoming less binary. In its 11 February 2026 announcement, Sutter Health described a collaboration intended to bring OpenEvidence's natural-language medical search into Epic workflows. That is evidence of an integration strategy, not proof that every Sutter clinician now has an identical live implementation.
OpenEvidence should therefore not be caricatured as a separate website indifferent to workflow. A preferred destination can also seek easier entry points. The strategically important question is whether those entry points preserve the experience people chose in the first place.
The current products do not all receive the same context
Tandem's CDS page, checked on 14 September 2026, describes source-linked answers using the documented visit as context, together with national guidance and uploaded local material. That is a specific product design, not a demonstration that all relevant patient information is always available.
Abridge's CDS description, checked on the same date, also presents answers informed by the conversation and clinical history. Its contextual approach belongs in this discussion even though the headline comparison begins with three better-known evidence-search propositions.
Heidi's Evidence page advertises cited answers, but its UK/EU access guidance makes an important distinction. As checked on 14 September, standalone access is separate from in-session Evidence; UK/EU patient/session linking is unavailable, and NHS UK email accounts are excluded from Evidence.
A UK comparison must retain those boundaries. It would be misleading to take a global demonstration of contextual assistance and assume that it describes the experience available to an NHS account.
Why more patient context can help, and why it can also mislead
Context can make a question more specific. It can also carry an incorrect assumption into the answer before the clinician notices. The issue is not whether patient information is inherently good or bad for a reference task, but whether the information used is relevant, current and correctly understood.
Consider a fictional educational record. An old note says an investigation was planned. A recent consultation says the patient does not know whether it occurred. The research question asks what evidence should inform a review discussion. A system that silently converts "planned" into "completed and normal" has changed the problem, however convincing its subsequent citations appear.
A useful evaluation would ask the system to distinguish documented findings, patient reports and missing information. The same standard should apply whether context arrives through an integration or is entered in a carefully constructed synthetic prompt.
A contextual answer therefore has two things to justify: its account of the case and its use of external evidence. A general reference answer has a narrower job, but still needs a well-defined population, setting and question. Neither should be scored solely on how fluent its final paragraph sounds.
What could defend a dedicated evidence product?
A reference tool can justify a deliberate visit when it handles an important question particularly well. Relevant advantages might include showing the exact supporting passage, explaining apparently conflicting recommendations, separating established guidance from emerging evidence, or making a specialist search easier to review.
Those are proposed evaluation criteria, not measured advantages of OpenEvidence over every competitor. The point is that additional navigation can be worthwhile when it produces a more usable answer. Conversely, familiarity with a brand should not excuse a poorly supported response.
Speed should be measured to the point at which the answer can be used responsibly. Generation time is only one part of that interval. Reading a long response, opening sources and resolving an unsupported statement can erase an apparent advantage in response latency.
The same applies to breadth. A larger collection of possible sources does not necessarily improve a bounded query. The valuable output is the evidence that actually addresses the question, with limitations visible enough to affect the conclusion.
A practical comparison that does not invent a winner
A service considering these products could use a paired exercise with original synthetic material. The first task would be a general reference question: "Which current sources distinguish screening from investigation for this topic in UK primary care, and what population does each source address?" The topic should be chosen and the reference standard agreed before testing.
The second task would add a fictional timeline containing an earlier plan, an uncertain result and a recent patient report. It would ask: "What information in this timeline is established, what remains unknown, and which sources would inform the subsequent discussion?" This tests whether context clarifies the question or introduces an unsupported premise.
Reviewers should record two results separately: the effort needed to reach and review an answer, and the fidelity of the answer to the case and sources. An integrated product could be easier to access but less complete on that task; a separate product could require more effort but expose an important uncertainty. The reverse is also possible.
Use matched account eligibility, preserve product versions and record the date. Do not compensate for one product's omission by giving it extra information after seeing another's output without documenting that change. Results should be published only after an actual run, with disputed judgements retained rather than quietly removed.
What OpenEvidence could do next
The Sutter collaboration supplies a factual starting point for considering deeper workflow partnerships. Further partnerships could make a preferred evidence experience easier to reach. That is a possible competitive response, not news of an undisclosed deal.
The other route is to make deliberate use more valuable: improve how the product resolves ambiguity, exposes conflicting sources and organises a difficult investigation. These priorities can coexist with integration rather than competing for a single strategic identity.
Model names are only part of that discussion. iatroX's existing Osler, Sackett and Snow guide explains the advertised task distinctions from the September 2026 launch. The separate question here is whether clinicians can obtain an appropriately supported answer with acceptable effort in their actual setting.
After the answer, a learning need may remain
This comparison is published by iatroX and includes Ask-iatroX. Its free UK-oriented reference uses sources including NICE, CKS, SIGN and SmPC information from emc. The published methodology, checked on 14 September 2026, describes retrieval, ranking, citation grounding, output checking and uncertainty handling. Those are design features to examine, not proof that every answer is correct.
For a clinician who notices a recurring knowledge gap, obtaining a reference answer need not be the last step. The Socratic Tutor, as described in September 2026, works with an attempted question and targeted follow-ups. That offers a different activity: examining the learner's reasoning rather than merely presenting another evidence summary.
There is no implied transfer of a patient record from OpenEvidence, Heidi, Tandem or Abridge into iatroX. A clinician can separately formulate a general learning need and practise without uploading identifiable clinical information. The product choice should follow the task, not an assumption that all work belongs in one conversation window.
Which first stop fits which reader?
For an eligible clinician already working in a supported contextual environment, an in-workflow answer may be a sensible starting point, provided its use of the record and sources can be reviewed. For a UK user facing account restrictions, actual access is a prerequisite, not a minor footnote.
For a researcher or specialist pursuing a difficult evidence question, a deliberately chosen reference destination may justify the additional step. For a learner trying to address a misunderstanding, a tutoring or practice session may be more useful than another search.
The competitive proposition is therefore not simply "be everywhere" or "give the deepest answer". An evidence platform must be useful enough that clinicians choose it, or accessible enough that trying it requires little additional effort, while still meeting the standard of source support the task requires.
Frequently asked questions
Is OpenEvidence only a standalone search destination?
No. Sutter Health announced an OpenEvidence collaboration for Epic workflows on 11 February 2026, although the announcement alone does not establish the status of every subsequent deployment.
Does patient context make a clinical AI answer more accurate?
Not automatically. Context can improve relevance, but missing, outdated or misinterpreted information can also change the question being answered.
Can Ask-iatroX be used alongside an organisation's documentation platform?
It can be chosen separately for appropriate reference and educational tasks. This article does not describe an integration or automated patient-data transfer between iatroX and the other products.